The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Shares of Gilead Sciences Inc. GILD advanced 2.46% to $111.11 Thursday, on what proved to be an all-around positive trading ...

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

This was the stock's second consecutive day of gains.

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

NORTHAMPTON, MA / ACCESS Newswire / May 30, 2025 / Gilead Sciences: We recently commemorated the opening of the Bay Area ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive ...